Using cell-free DNA to diagnose pancreatic cancer
Cell-free Chromatin Immunoprecipitation (CfChIP) from Blood Plasma As a Diagnostic and Prognostic Tool in Pancreatic Ductal Adenocarcinoma
University of Central Florida · NCT06148298
This study is testing whether a new blood test that looks at cell-free DNA can help diagnose pancreatic cancer earlier and more easily than current methods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 24 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Central Florida (other) |
| Locations | 1 site (Orlando, Florida) |
| Trial ID | NCT06148298 on ClinicalTrials.gov |
What this trial studies
This research aims to utilize chromatin immunoprecipitation (ChIP) to analyze cell-free DNA for diagnosing and prognosing pancreatic ductal adenocarcinoma (PDAC). By focusing on protein-DNA interactions, the study seeks to identify tumor-specific transcriptional activity in human samples. Given the high mortality rate associated with late-stage PDAC, this approach could provide a non-invasive and cost-effective alternative to traditional screening methods like MRI. The study emphasizes the potential of liquid biopsy techniques to enhance early detection and improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with pancreatic cancer.
Not a fit: Patients who are under 18 years old or unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this method could lead to earlier and more accurate diagnoses of pancreatic cancer, potentially improving survival rates.
How similar studies have performed: While few studies have explored the use of ChIP in liquid biopsies for pancreatic cancer, other liquid biopsy approaches have shown promise, indicating potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years old or older * Pancreatic cancer patients Exclusion Criteria: * Children may not register * Persons who are unable to consent may not register
Where this trial is running
Orlando, Florida
- University of Central Florida — Orlando, Florida, United States (RECRUITING)
Study contacts
- Principal investigator: Kersten Schroeder, PhD — University of Central Florida
- Study coordinator: Amoy Fraser, PhD, CCRP, PMP
- Email: amoy.fraser@ucf.edu
- Phone: 4072668742
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer of Pancreas, cancer, pancreas